GentiBio
Alberto del Rio Espinola is Director of Translational Sciences at GentiBio. He holds Biotechnology and Biochemistry degrees from Autonoma de Barcelona University and his Ph.D. in pharmacogenetics of stroke acute therapy from Vall d’Hebron Hospital. During his time with Novartis in Basel, Switzerland, Alberto started as a computational biologist applying pharmacogenetics to safety endpoints, he went on to work in a project toxicologist role for advanced therapy programs and then led a laboratory using genome engineering as a tool to support safety evaluation. Alberto is certified by the American Board of Toxicology and by European Registry.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.